Presented at #ESCMIDGlobal2026:
📊 Research Summary: In patients with #GramNegativeBacteremia, rapid #AntimicrobialSusceptibilityTesting did not improve 30-day outcomes compared with standard testing, although it supported faster antibiotic adjustments.
https://ja.ma/3QkoI0X
Presented at #ESCMIDGlobal2026:
💬 Editorial: In a multinational trial, #RapidAST did not improve a composite clinical outcome but led to earlier antibiotic optimization and shorter hospitalization in patients with resistant gram‑negative infections.
https://ja.ma/48chpi1
R to @JAMANetworkOpen: 💬 Read the JAMA editorial, "New Pathways to Treat Staphylococcus aureus Bacteremia":
The DOTS trial provides the best data available to date on the use of long-acting lipoglycopeptides as consolidation therapy for complicated S aureus bacteremia.
https://ja.ma/4u0Nou1
R to @JAMANetworkOpen: 📊 Read the JAMA article, "Dalbavancin for Treatment of Staphylococcus aureus Bacteremia":
Among adults with complicated Staphylococcus aureus bacteremia, dalbavancin was not superior to standard therapy, though both treatments demonstrated similar efficacy and safety profiles.
https://ja.ma/4u0Nwtv
Presented at #ESCMIDGlobal2026 from @JAMANetworkOpen:
In a pre-planned exploratory analysis of the DOTS RCT, achieving a total day-22 dalbavancin concentration >32 µg/mL was associated with higher rates of clinical success in patients with complicated Staphylococcus aureus bacteremia.
https://ja.ma/41GG8r8
Among patients with #GramNegativeBacteremia, rapid #AntimicrobialSusceptibilityTesting did not improve 30-day clinical outcomes compared with standard testing, despite providing faster guidance for antibiotic escalation or deescalation.
#ESCMIDGlobal2026
https://ja.ma/4mAFzbM
In this podcast, JAMA Deputy Editors Linda Brubaker, MD, and Preeti Malani, MD, MSJ, discussed the latest science published in JAMA:
➡️ Transcatheter Tricuspid Valve Replacement Outcomes,
➡️ Tobramycin for Surgical Site Infection in Tibial Fracture,
➡️ AI Drug Prescribing, and more.
🎧 Listen now: https://ja.ma/4mCDhZC
💬 Viewpoint: Routine public release of FDA complete response letters marks progress, but broader transparency—including disclosure of drug and device application filings—remains needed.
https://ja.ma/4tlSFwg
R to @JAMANetworkOpen: 💬 Editorial: The DOTS trial provides the best data available to date on the use of long-acting lipoglycopeptides as consolidation therapy for complicated S aureus bacteremia.
https://ja.ma/4tScbjH
R to @JAMANetworkOpen: Among adults with complicated Staphylococcus aureus bacteremia, dalbavancin was not superior to standard therapy, though both treatments demonstrated similar efficacy and safety profiles.
https://ja.ma/4tieywd
From @JAMANetworkOpen: In a pre-planned exploratory analysis of the DOTS RCT, achieving a total day-22 dalbavancin concentration >32 µg/mL was associated with higher rates of clinical success in patients with complicated Staphylococcus aureus bacteremia. 🧵
#ESCMIDGlobal2026 @ESCMID
https://ja.ma/3Qlu1x6
Among adults with #AcuteSinusitis, standard-dose amoxicillin-clavulanate did not reduce treatment failure compared with amoxicillin, while overall failure and hospitalization rates were low in both groups.
#ESCMIDGlobal2026 @ESCMID
https://ja.ma/4ufKxxx
R to @JAMA_current: 💬 Editorial: Children surviving cerebral #malaria or severe malarial anemia face long‑term cognitive and academic deficits years after infection, highlighting that the burden of #Malaria extends far beyond hospital discharge.
#ESCMIDGlobal2026 @ESCMID
https://ja.ma/3QNgQVN
Children with prior #CerebralMalaria or severe malarial anemia had lower long-term cognitive ability and math achievement than unaffected children when assessed up to 15 years later, while attention and reading scores were similar. 🧵
#ESCMIDGlobal2026 @ESCMID
https://ja.ma/41KnnD5
R to @JAMA_current: 📊 Research Summary: In patients with #GramNegativeBacteremia, rapid #AntimicrobialSusceptibilityTesting did not improve 30-day outcomes compared with standard testing, although it supported faster antibiotic adjustments.
#ESCMIDGlobal2026 @ESCMID
https://ja.ma/4sERdDW
R to @JAMA_current: 💬 Editorial: In a multinational trial, #RapidAST did not improve a composite clinical outcome but led to earlier antibiotic optimization and shorter hospitalization in patients with resistant gram‑negative infections.
#ESCMIDGlobal2026 @ESCMID
https://ja.ma/4vBO7Dv
Among patients with #GramNegativeBacteremia, rapid #AntimicrobialSusceptibilityTesting did not improve 30-day clinical outcomes compared with standard testing, despite providing faster guidance for antibiotic escalation or deescalation. 🧵
#ESCMIDGlobal2026 @ESCMID
https://ja.ma/4sL7JlU
💬 Perspective: Cuts to social welfare, health agencies, and data surveillance are projected to increase mortality rates and escalate the US health disadvantage relative to other nations.
https://ja.ma/4cCJG2x
📍 At ##ESCMIDGlobal2026?
Join the Late-breaking research from JAMA: novel insights on treating and preventing infections around the world:
📅 Today, April 18
⏰ 13:30 - 14:30
📍 Hall A2-1
Chaired by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief of JAMA and the JAMA Network, and Preeti Malani, MD, MSJ, Deputy Editor of JAMA.
📍 At ##ESCMIDGlobal2026?
Join the Late-breaking research from JAMA: novel insights on treating and preventing infections around the world:
📅 Today, April 18
⏰ 13:30 - 14:30
📍 Hall A2-1
Chaired by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief of JAMA and the JAMA Network, and Preeti Malani, MD, MSJ, Deputy Editor of JAMA.
Med News: A new independent autism committee has launched in the US in response to shifts in the longstanding federal Interagency Autism Coordinating Committee.
https://ja.ma/4teI7ij
Med News: The highly mutated SARS-CoV-2 variant BA.3.2, nicknamed Cicada, is emerging after an extended period of lying low. Here’s what to know about the latest Variant Under Monitoring. #COVID19
https://ja.ma/4eobHgM
In a Viewpoint for @JAMA_current, #BULawProf @ProfCRobertson and Daniel Aaron (@sjquinney) discuss Utah’s partnership with an AI company to prescribe medications without physician involvement.
Learn more ⬇️ http://spr.ly/6014B64ZVq
💬 Viewpoint: Panelists who advised removing box warnings from #Menopausal hormone therapies were selected outside the standard FDA advisory process, lacked public input, and did not review all available evidence. https://ja.ma/4262sKN
In this JAMA video, Derek C. Angus, MD, MPH, of the University of Pittsburgh School of Medicine and a JAMA Senior Editor, discusses 5 areas of research that could benefit care for critically ill patients. https://ja.ma/41yc6Wl
💬 Viewpoint: Mandatory annual training modules consume millions of physician‑hours each year, yet their largely passive formats may offer limited educational value while contributing to administrative burden and clinician burnout.
https://ja.ma/4vvyvBm
"Medicine can have extraordinary meaning. But it cannot substitute for being present in your own life."
In #APieceofMyMind, a psychiatrist and residency program director reflects on an unexpected #LungCancer diagnosis.
https://ja.ma/48OxHxC
💬 Editorial: Rising mortality rates in #ICEDetention during fiscal years 2024 through partial 2026 coincided with rapid detention expansion and reduced oversight, raising concerns about health care delivery and monitoring.
https://ja.ma/4tnhic4
Analysis of publicly reported data identified 272 deaths in #ICEDetention from fiscal year 2004 through January 2026, with mortality rates declining early in the period and increasing again in recent fiscal years.
https://ja.ma/4dSo98j
💬 Editorial: Routine physical restraints in mechanically ventilated ICU patients did not alter delirium, self-extubation, or mortality rates; individualized assessment is imperative in #CriticalCare.
https://ja.ma/4tLow9f
A restrictive (lower use) wrist-strap restraint approach did not improve delirium-free or coma-free days compared to liberal use in mechanically ventilated ICU patients. https://ja.ma/4tOYi5R
Med News: The US EPA’s rollback of heavy metal air pollution rules for coal-fired power plants may put public health at risk, experts warn. https://ja.ma/4sub9cv
💬 Viewpoint: Differences in rebate design across the GLOBE, GUARD, and GENEROUS models mean reductions in federal drug spending may not consistently translate into lower out-of-pocket costs for #Medicare or #Medicaid beneficiaries.
https://ja.ma/4mtuzNj
📊 JAMA Clinical Challenge: In adults, generalized vesicular #Rash with hypoxia and pulmonary infiltrates should prompt evaluation for #Varicella pneumonia and initiation of intravenous #Acyclovir.
https://ja.ma/3OhcJk9
💬 Editorial: Virtual and remote #ClinicalTrials can expand access and capture real‑world outcomes, but they require careful design to address data quality, patient safety monitoring, and participant engagement without in‑person contact.
https://ja.ma/4muoXCJ
📊 Research Summary: In a randomized clinical trial, intrawound tobramycin plus vancomycin offered no added benefit over vancomycin alone for preventing deep #SurgicalSiteInfection after definitive tibial fracture fixation.
https://ja.ma/3OmGT5y
Among patients undergoing surgery for high-risk periarticular #TibialFracture, adding intrawound tobramycin to vancomycin did not reduce deep #SurgicalSiteInfection compared with vancomycin alone.
https://ja.ma/4tc7d1b
Led by Editor in Chief Alison Huang, MD, MAS, JAMA+ Trials brings together recent clinical trial reports from the 13 JAMA Network journals, multimedia explorations of emerging trends, and educational resources on trial design, conduct, and reporting.
📝 Read the launch editorial: https://ja.ma/4dOqi51
📬 Sign up for the JAMA+ Trials email newsletter: https://ja.ma/4mx0WdZ
👉 Follow JAMA+ Trials on X: @JAMAplusTrials
💬 Viewpoint: Utah authorized the first autonomous #AI drug prescriber for nearly 200 medications, bypassing physician oversight and FDA review, raising questions about safety and regulatory gaps.
https://ja.ma/47YBGrk
Uterine cancer is the fourth most common cancer in women in the US, with an estimated 68 270 new cases and 14 450 cancer deaths projected to occur in 2026.
📄 This Review summarizes the epidemiology, clinical presentation, and diagnosis of endometrial cancer.
https://ja.ma/4dU90DD